Celldex Therapeutics, Inc. (CLDX)

39.12 -3.31% (-1.34)

Over 5Y: -21.8%

2026-08-28
20 40
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 153K Q3 '21 — Operating Cash Flow: -16.4M Q3 '21 — Free Cash Flow: -16.6M Q3 '21 — Net Income: -20.5M Q4 '21 — Revenue: 334K Q4 '21 — Operating Cash Flow: -14.5M Q4 '21 — Free Cash Flow: -14.9M Q4 '21 — Net Income: -20.1M Q1 '22 — Revenue: 174K Q1 '22 — Operating Cash Flow: -24.5M Q1 '22 — Free Cash Flow: -25.1M Q1 '22 — Net Income: -23.1M Q2 '22 — Revenue: 163K Q2 '22 — Operating Cash Flow: -22.2M Q2 '22 — Free Cash Flow: -22.9M Q2 '22 — Net Income: -36M Q3 '22 — Revenue: 407K Q3 '22 — Operating Cash Flow: -35.2M Q3 '22 — Free Cash Flow: -35.5M Q3 '22 — Net Income: -26.8M Q4 '22 — Revenue: 1.6M Q4 '22 — Operating Cash Flow: -21.8M Q4 '22 — Free Cash Flow: -22M Q4 '22 — Net Income: -26.5M Q1 '23 — Revenue: 967K Q1 '23 — Operating Cash Flow: -28.6M Q1 '23 — Free Cash Flow: -29.2M Q1 '23 — Net Income: -29.4M Q2 '23 — Revenue: 268K Q2 '23 — Operating Cash Flow: -27.2M Q2 '23 — Free Cash Flow: -27.6M Q2 '23 — Net Income: -30.5M Q3 '23 — Revenue: 1.5M Q3 '23 — Operating Cash Flow: -19M Q3 '23 — Free Cash Flow: -19.1M Q3 '23 — Net Income: -38.3M Q4 '23 — Revenue: 4.1M Q4 '23 — Operating Cash Flow: -32.5M Q4 '23 — Free Cash Flow: -33.2M Q4 '23 — Net Income: -43.3M Q1 '24 — Revenue: 156K Q1 '24 — Operating Cash Flow: -40.6M Q1 '24 — Free Cash Flow: -41M Q1 '24 — Net Income: -32.8M Q2 '24 — Revenue: 2.5M Q2 '24 — Operating Cash Flow: -29.3M Q2 '24 — Free Cash Flow: -29.6M Q2 '24 — Net Income: -35.8M Q3 '24 — Revenue: 3.2M Q3 '24 — Operating Cash Flow: -55.3M Q3 '24 — Free Cash Flow: -55.9M Q3 '24 — Net Income: -42.1M Q4 '24 — Revenue: 1.2M Q4 '24 — Operating Cash Flow: -32.5M Q4 '24 — Free Cash Flow: -33.2M Q4 '24 — Net Income: -47.1M Q1 '25 — Revenue: 695K Q1 '25 — Operating Cash Flow: -54.4M Q1 '25 — Free Cash Flow: -54.6M Q1 '25 — Net Income: -53.8M Q2 '25 — Revenue: 730K Q2 '25 — Operating Cash Flow: -44M Q2 '25 — Free Cash Flow: -44.7M Q2 '25 — Net Income: -56.6M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -48.6M Q3 '25 — Free Cash Flow: -49.1M Q3 '25 — Net Income: -67M Q4 '25 — Revenue: 121K Q4 '25 — Operating Cash Flow: -63.9M Q4 '25 — Free Cash Flow: -65.2M Q4 '25 — Net Income: -81.3M Q1 '26 — Revenue: 15K Q1 '26 — Operating Cash Flow: -65.6M Q1 '26 — Free Cash Flow: -67.2M Q1 '26 — Net Income: -78.7M Q2 '26 — Revenue: 22K Q2 '26 — Operating Cash Flow: -57.4M Q2 '26 — Free Cash Flow: -60.6M Q2 '26 — Net Income: -73.5M -80M -60M -40M -20M 0 20M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
Accruals -8.3%
Asset turnover 0.0002×
ROA -38.4%
ROCE -45.2%
ROE -42.1%
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
ROIC —
SBC / sales —

0 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.8
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.5
Current ratio 11.8×
ND/EBITDA —
Cash runway 3.0 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 11.8×
F-score 1.1 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -24.1%
Sales/sh Y/Y -97.4%
Sales Q/Q -97.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.